Cynapsus Therapeutics Inc Share Price

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

03/06	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
03/06	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

03/06	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
03/06	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
03/06	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
20/05	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
11/24/11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
29/24/29	CoTec Holdings Outlines Key Targets For 2024	MT
03/24/03	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
10/23/10	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
10/23/10	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
02/23/02	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
14/23/14	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
14/23/14	CoTec Holdings, Mkango To Form US Joint Venture	MT
30/23/30	Kings Chapel Increases Stake In CoTec Holdings	MT

06/05	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
01/16/01	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/16/29	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/16/15	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/16/12	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	-1.79%	-3.82%	+38.74%	+91.90%	6.9TCr
ARGENX SE	-2.06%	-0.18%	+41.53%	+88.17%	6.63TCr
INSMED INCORPORATED	-0.40%	+6.19%	-11.68%	+377.36%	2.77TCr
BIONTECH SE	+1.61%	+2.32%	+0.91%	-14.39%	2.58TCr
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.61%	+34.45%	+11.39%	2.65TCr
GENMAB A/S	-1.46%	+0.42%	+24.07%	-18.70%	2.04TCr
PHARMAESSENTIA CORPORATION	-2.96%	-16.03%	+213.13%	+375.00%	1.76TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.69%	-4.69%	+539.74%	1.51TCr
EXELIXIS, INC.	-0.10%	+8.43%	+57.95%	+165.11%	1.47TCr
Average	-1.16%	-0.66%	+43.82%	+179.51%	3.15TCr
Weighted average by Cap.	-1.47%	-0.45%	+39.08%	+139.06%